In silico clinical trials for pediatric orphan diseases
暂无分享,去创建一个
L. Geris | M. Marechal | L. Geris | J. de Boer | M. Maréchal | A. Carlier | A. Vasilevich | L. Geris | A. Carlier | A. Vasilevich | J. de Boer | J. Boer | A. Carlier | J. de Boer
[1] R. Margraf,et al. Evaluation of somatic mutations in tibial pseudarthrosis samples in neurofibromatosis type 1 , 2015, Journal of Medical Genetics.
[2] Jonathan C. Craig,et al. Clinical trials in children. , 2015, British journal of clinical pharmacology.
[3] Jos Vander Sloten,et al. Occurrence and Treatment of Bone Atrophic Non-Unions Investigated by an Integrative Approach , 2010, PLoS Comput. Biol..
[4] S. Mundlos,et al. Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin , 2008, BMC medicine.
[5] M. Lazebnik,et al. Safe magnetic resonance imaging scanning of patients with cardiac rhythm devices: a role for computer modeling. , 2013, Heart rhythm.
[6] Pras Pathmanathan,et al. Ensuring reliability of safety-critical clinical applications of computational cardiac models , 2013, Front. Physiol..
[7] J. Carey,et al. Double inactivation of NF1 in tibial pseudarthrosis. , 2006, American journal of human genetics.
[8] I. Alexander,et al. A murine model of neurofibromatosis type 1 tibial pseudarthrosis featuring proliferative fibrous tissue and osteoclast‐like cells , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[9] Peter A Merkel,et al. Clinical research for rare disease: opportunities, challenges, and solutions. , 2009, Molecular genetics and metabolism.
[10] Jeffrey Shuren,et al. An FDA Viewpoint on Unique Considerations for Medical-Device Clinical Trials. , 2017, The New England journal of medicine.
[11] Jiang Yao,et al. Determining the most important cellular characteristics for fracture healing using design of experiments methods. , 2008, Journal of theoretical biology.
[12] Liesbet Geris,et al. Size Does Matter: An Integrative In Vivo-In Silico Approach for the Treatment of Critical Size Bone Defects , 2014, PLoS Comput. Biol..
[13] M. Viceconti,et al. Patient-specific finite element estimated femur strength as a predictor of the risk of hip fracture: the effect of methodological determinants , 2016, Osteoporosis International.
[14] H Van Oosterwyck,et al. Designing optimal calcium phosphate scaffold-cell combinations using an integrative model-based approach. , 2011, Acta biomaterialia.
[15] Andy Liaw,et al. Classification and Regression by randomForest , 2007 .
[16] W. Friess,et al. Collagen sponges for bone regeneration with rhBMP-2. , 2003, Advanced drug delivery reviews.
[17] C. Cobelli,et al. In Silico Preclinical Trials: A Proof of Concept in Closed-Loop Control of Type 1 Diabetes , 2009, Journal of diabetes science and technology.
[18] Ralf-Dieter Hilgers,et al. Directions for new developments on statistical design and analysis of small population group trials , 2016, Orphanet Journal of Rare Diseases.
[19] Aaron Schindeler,et al. Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1). , 2008, Bone.
[20] B. S. Richards,et al. rhBMP-2 and Intramedullary Fixation in Congenital Pseudarthrosis of the Tibia , 2016, Journal of pediatric orthopedics.
[21] Campbell O. Webb,et al. Picante: R tools for integrating phylogenies and ecology , 2010, Bioinform..
[22] Paul F. Reynolds,et al. The Role of Modeling and Simulation , 2008 .
[23] In Ho Choi,et al. Treatment of congenital pseudarthrosis of the tibia with recombinant human bone morphogenetic protein-7 (rhBMP-7). A report of five cases. , 2006, The Journal of bone and joint surgery. American volume.
[24] M. Karlsson,et al. The Role of Modeling and Simulation in Development and Registration of Medicinal Products: Output From the EFPIA/EMA Modeling and Simulation Workshop , 2013, CPT: pharmacometrics & systems pharmacology.
[25] J. Rueger,et al. Combined treatment of congenital pseudarthrosis of the tibia, including recombinant human bone morphogenetic protein-2: a case series. , 2011, The Journal of bone and joint surgery. British volume.
[26] Liesbet Geris,et al. Oxygen as a critical determinant of bone fracture healing-a multiscale model. , 2015, Journal of theoretical biology.
[27] Aris Angelis,et al. Socio-economic burden of rare diseases: A systematic review of cost of illness evidence. , 2015, Health policy.
[28] David Gavaghan,et al. Multi-scale computational modelling in biology and physiology , 2007, Progress in Biophysics and Molecular Biology.
[29] L. Geris,et al. Capturing the wide variety of impaired fracture healing phenotypes in Neurofibromatosis Type 1 with eight key factors: a computational study , 2016, Scientific Reports.
[30] M. Viceconti,et al. Biomechanical robustness of a new proximal epiphyseal hip replacement to patient variability and surgical uncertainties: a FE study. , 2012, Medical engineering & physics.
[31] G. Clermont,et al. In silico design of clinical trials: A method coming of age , 2004, Critical care medicine.
[32] John G. Holden,et al. A fractal approach to dynamic inference and distribution analysis , 2013, Front. Physio..
[33] C. Wahlestedt,et al. Orphan diseases: state of the drug discovery art , 2017, Wiener Medizinische Wochenschrift.
[34] B. Dohin,et al. Masquelet’s procedure and bone morphogenetic protein in congenital pseudarthrosis of the tibia in children: a case series and meta-analysis , 2012, Journal of children's orthopaedics.
[35] Marco Viceconti,et al. In silico clinical trials: how computer simulation will transform the biomedical industry , 2016 .
[37] R. Atit,et al. The Nf1 tumor suppressor regulates mouse skin wound healing, fibroblast proliferation, and collagen deposited by fibroblasts. , 1999, The Journal of investigative dermatology.
[38] Y. Tabata,et al. Enhanced osteoinduction by controlled release of bone morphogenetic protein-2 from biodegradable sponge composed of gelatin and beta-tricalcium phosphate. , 2005, Biomaterials.